Imaging and Biomarker Core

摘要 影像和生物标记物(IB)核心将通过神经成像来表征临床核心的参与者 和流体生物标志物分析，符合现行标准。另一个重点是严格地描述 并将这一信息与认知、流体生物标记物、遗传、 和由该中心产生的神经病理数据。核心还将提供一个信息架构和 咨询专业知识，向ADRC附属研究和调查人员提供成像数据。 许多华盛顿大学ADRC附属研究要求受试者具有良好的成像和 流体生物标志物。将对所有正常认知、MCI和轻度AD参与者进行MRI成像 临床和本地研究与资源(NRRC)核心。我们将以以下方式描述我们的临床核心队列 A|T|N分型，主要结合脑脊液生物标志物(A、T)和磁共振成像(N)。IB核心将协调 在ADRC附属项目中进行PET扫描或在临床核心中联合招募附属受试者以确保临床核心 受试者接受正电子发射计算机断层扫描。我们提供规划和分析PET分子的专业知识 影像研究。 附属研究正在调查AD的具体候选机制，以及是否和为什么， 阿尔茨海默病固有的不同病理机制对大脑皮层的影响方式不同。为 这样的研究表明，大脑空间是AD其他生物标志物的一个集成点。我们已经组织了IB CORE及其与临床和神经病理核心的相互作用， 根据成像数据确定，作为表型特征与认知域、流体结合在一起 生物标记物和基因数据。我们将在一组测试中测量皮质退行性变以及皮质备用 代表参与阿尔茨海默病的范围和变异性的大脑区域。的另一个重要方面 认知变异性是由给定程度的认知障碍引起的认知损害程度之间的关系 神经退行性变(认知弹性)。因此，我们还将从以下方面提取认知弹性的测量 认知和解剖数据，作为另一个表型维度。我们将在以下方面提供咨询专业知识 信息学/机器学习、图像分析和统计，用于描述和分析这些数据。 我们还构建了核心，以支持相同的多学科表型 来验尸的临床队列。我们将全部进行体外核磁共振检查，并进行结构性措施 在活体研究中也是如此。我们将从我们在生活中进行成像的相同区域提取组织样本 参与者。我们将计算类似的弹性衡量标准。体外核磁共振也将实现有针对性的采样 MRI-尸检时的明显异常，并将神经病理数据映射到标准解剖空间。

Abstract The Imaging and Biomarker (IB) Core will characterize participants in the Clinical Core through neuroimaging and fluid biomarker analysis, in conformity with prevailing standards. A further focus is to rigorously describe topographic phenotypes of the participants and to link this information to cognitive, fluid biomarker, genetic, and neuropathologic data generated by the Center. The Core will also provide an information architecture and consulting expertise to represent the imaging data to ADRC-affiliated studies and investigators. Many UW ADRC-affiliated studies require human subjects who are well-characterized with imaging and fluid biomarkers. MRI imaging will be obtained on all normal cognition, MCI, and mild AD participants in the Clinical and Native Research and Resource (NRRC) Cores. We will characterize our Clinical Core cohort with A|T|N classification, primarily with CSF biomarkers (A, T) and MRI (N) imaging. The IB Core will coordinate PET scans in ADRC affiliate projects or co-enroll affiliate subjects in the Clinical Core to ensure Clinical Core subjects have PET scanning performed. We provide expertise in planning and analyzing PET molecular imaging studies. Affiliated studies are investigating specific candidate mechanisms of AD, as well as whether, and why, different pathological mechanisms inherent in AD have differing patterns of impact over the cerebral cortex. For such studies, the brain space is a point of integration of the other biomarkers of AD. We have organized the IB Core and its interactions with the Clinical and Neuropathology Cores such that topographical heterogeneity, determined from imaging data, is incorporated as a phenotypic characteristic, along with cognitive domain, fluid biomarker, and genetic data. We will measure cortical degeneration, as well as cortical sparing, across a set of brain regions that represent the range and variability of involvement in AD. Another important aspect of cognitive variability is the relationship of the degree of cognitive impairment that results from a given degree of neurodegeneration (cognitive resilience). Thus we will also extract measures of cognitive resilience from cognitive and anatomic data, as another phenotypic dimension. We will provide consulting expertise in informatics/machine learning, image analysis and statistics for the description and analysis of these data. We have also structured the Core to support the same multidisciplinary phenotyping in decedents from the Clinical cohort who come to autopsy. We will perform ex vivo MRI in all, and process structural measures as in the in vivo studies. We will sample tissue from the same regions that we target with imaging in living participants. We will calculate analogous resilience measures. Ex vivo MRI will also enable targeted sampling of MRI-apparent abnormalities at autopsy and mapping neuropathologic data into standard anatomical space.